# A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

> **NCT00615056** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 171 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Bevacizumab (avastin)
- **DRUG:** FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
- **DRUG:** AG-013736 (axitinib)
- **DRUG:** FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
- **DRUG:** AG-013736 (axitinib)
- **DRUG:** FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])
- **DRUG:** Bevacizumab (avastin)
- **DRUG:** FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])

## Key facts

- **NCT ID:** NCT00615056
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-03
- **Final completion:** 2012-04
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2013-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00615056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00615056, "A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00615056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*